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Summary
Background The ‘treat to target’ paradigm improves outcomes and reduces costs in
chronic disease management but is not yet established in psoriasis.
Objectives To identify treatment targets in psoriasis using two common measures
of disease activity: Psoriasis Area and Severity Index (PASI) and Physician’s Global
Assessment (PGA).
Methods Data from a multicentre longitudinal U.K. cohort of patients with psoriasis
receiving systemic or biologic therapies (British Association of Dermatologists Bio-
logics and Immunomodulators Register, BADBIR) were used to identify absolute
PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline dis-
ease activity, using receiver operating characteristic curves. The relationship between
PGA (clear, almost clear, mild, moderate, moderate–severe, severe) and PASI (range
0–72) was described, and the concordance between absolute and relative definitions
of response was determined. The same approach was used to establish treatment
response and eligibility definitions based on PGA.
Results Data from 13 422 patients were available (58% male, 91% white ethnicity,
mean age 449 years), including over 23 000 longitudinal PASI and PGA scores. An
absolute PASI ≤ 2 was concordant with PASI 90 and an absolute PASI ≤ 4 was concor-
dant with PASI 75 in 90% and 88% of cases, respectively. These findings were robust
to subgroups of timing of assessment, baseline disease severity and treatment modal-
ity. PASI and PGA were strongly correlated (Spearman’s rank correlation coefficient
092). The median PASI increased from 0 (interquartile range 0–0, range 0–23) to
19 (interquartile range 15–25, range 0–64) for PGA clear to severe, respectively.
PGA clear/almost clear was concordant with PASI ≤ 2 in 90% of cases, and PGA
moderate–severe severe was concordant with the National Institute for Health and
Care Excellence PASI eligibility criteria for biologics in 81% of cases.
Conclusions An absolute PASI ≤ 2 and PGA clear/almost clear represent relevant
disease end points to inform treat-to-target management strategies in psoriasis.
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What’s already known about this topic?
• The most commonly used relative disease activity measure in psoriasis is ≥ 90%
improvement in Psoriasis Area and Severity Index (PASI 90); however, it has sev-
eral limitations including dependency on a baseline severity assessment.
• Defining an absolute target disease activity end point in psoriasis has the potential
to improve patient outcomes and reduce costs, as demonstrated by treat-to-target
approaches in other chronic diseases such as hypertension and diabetes.
• The Physician’s Global Assessment (PGA) is a popular alternative measure of psori-
asis severity in daily practice; however, its utility has not been formally assessed
with respect to PASI.
What does this study add?
• An absolute PASI ≤ 2 corresponds with PASI 90 response and is a relevant disease
end point for treat-to-target approaches in psoriasis.
• There is a strong correlation between PASI and PGA.
• PGA moderate–severe/severe may serve as an alternative eligibility criterion for
biologics to PASI-based definitions, and PGA clear/almost clear is an appropriate
alternative absolute treatment end point.
What are the clinical implications of this work?
• Absolute PASI ≤ 2 and PGA clear/almost clear represent relevant disease end points
to inform treat-to-target management strategies in psoriasis.
Psoriasis is a chronic, inflammatory skin disease that is recog-
nized as a major global health problem by the World Health
Organization and affects 2–4% of the population.1 It is asso-
ciated with reduced quality of life and multiple morbidities
including psoriatic arthritis, cardiovascular disease, obesity
and depression.2 Recent insights into the molecular pathogen-
esis of psoriasis have led to the development of increasingly
effective targeted therapies, which have transformed patient
and clinician expectations of treatment3 and improved
comorbidity outcomes.4 In this context, a robust target dis-
ease activity end point is needed to drive the introduction
and modification of treatments in a timely, effective and
cost-efficient manner. This ‘treat to target’ paradigm is well
established in cardiology (hypertension, hyperlipidaemia),
endocrinology (diabetes mellitus) and rheumatology
(rheumatoid arthritis), and can improve patient outcomes
and reduce costs.5,6
In psoriasis, the disease activity end point is currently
defined by a relative change from baseline rather than an
absolute measure, using the Psoriasis Area and Severity
Index (PASI; range 0–72).6–8 PASI 75 (≥ 75% improvement
in PASI from baseline) and, increasingly, PASI 90, are com-
mon primary end points in interventional clinical trials7 and
parallel clinically relevant improvements in patient-reported
outcomes [Dermatology Life Quality Index (DLQI) 0 or 1].8
These end points have driven treatment guideline
recommendations on eligibility and response to psoriasis
interventions.9,10 However, in clinical practice the accuracy
and relevance of relative (in contrast to absolute) PASI mea-
sures are limited by a dependence on the baseline PASI.
This may have been established historically or be uncertain
due to the chronic nature of the disease and variability in
washout of prior systemic therapies. There is also potential
for interassessor variability of current vs. baseline PASI mea-
surements.
Aside from difficulties related to use of a baseline assessment
to inform a treatment target, there are also limitations with the
measure itself. Separate calculations of extent and intensity of
plaques of psoriasis at four anatomical regions (head, trunk, and
upper and lower extremities) may be challenging in time-
pressed routine practice11 and introduce potential for interasses-
sor variation and calculation errors. There is limited sensitivity
for evaluating patients with low levels of disease, redundancy at
the upper half of the range for PASI and a paucity of data on the
utility of PASI in real-world as opposed to trial settings.12 The
Physician’s Global Assessment (PGA) may be a useful alternative
measure for daily practice, as it is a simple, average assessment
of all psoriasis lesions according to a Likert scale (six-point score
in the European Medicines Agency guidelines: clear, almost
clear, mild, moderate, moderate–severe, severe).13 However,
there has been no formal assessment of its utility with respect to
PASI in routine practice.
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In this study we used a large-scale real-world multicentre
longitudinal cohort of patients receiving systemic therapies
(the British Association of Dermatologists Biologics and
Immunomodulators Register, BADBIR)14 to establish an abso-
lute definition of disease control based on the most widely
used relative measure, PASI 90. The clinical utility of PGA was
investigated by determining the relationship between PASI and
PGA, and exploring how this relates to current PASI-based def-
initions of treatment eligibility and response using the U.K.
exemplar National Institute for Health and Care Excellence
(NICE) criteria.9
Patients and methods
Study design and setting
This study uses data from BADBIR, which is a U.K. and Republic
of Ireland multicentre pharmacovigilance registry (research
ethics committee reference 07/MRE08/9). BADBIR was estab-
lished in 2007 for individuals with psoriasis starting on systemic
therapies and aged 16 years or older, and is described in detail
elsewhere (http://www.badbir.org).14,15 It includes detailed
demographic and longitudinal clinical data on all participants
including regular multimodal disease severity and treatment
outcome measurements such as PASI and PGA. Baseline assess-
ments are completed within the first 6 months of treatment
(183 to 0 days) and follow-up visits are at 6-monthly intervals
for the first 3 years and then annually to 10 years. The data cut-
off for this analysis is 1 April 2018.
Individuals with a diagnosis of psoriasis under the care of a
dermatologist, started on or switched to a biologic (for the ‘bio-
logic cohort’) or nonbiologic systemic therapy (for the ‘nonbio-
logic systemic cohort’) within the previous 6 months and able
to give informed consent are eligible for inclusion. Individuals
in the ‘nonbiologic systemic cohort’ have PASI ≥ 10 and DLQI
>10 (unless switching between nonbiologic systemic agents)
and have no prior exposure to a biologic agent.14 There are no
minimum PASI or DLQI inclusion criteria for participants in the
‘biologic cohort’, as eligibility for biologic therapy according to
the NICE criteria is assumed (PASI ≥ 10 and DLQI > 10).9
Outcome measures
PASI scores are measured consecutively over time for each par-
ticipant, and the primary outcome measure of treatment
response is defined as PASI 90, which is the most widely used
standard primary outcome in psoriasis. PASI 75 response is
analysed as a secondary outcome.
Statistical methods
Identifying an absolute Psoriasis Area and Severity Index
(PASI) threshold that corresponds to PASI 90 and PASI 75
Receiver operating characteristic (ROC) curves are used on the
longitudinal PASI data in BADBIR to establish absolute PASI
thresholds corresponding to PASI 90 and PASI 75 responses.
Individuals with a missing baseline PASI are not included. As
PASI 90 and PASI 75 are calculated with respect to baseline
PASI, mathematical coupling16 between the relative and abso-
lute PASI values would inflate the statistical measures derived
from the ROC curve. Therefore, ROC curves are used to
inform cut point locations based on maximizing the sum of
sensitivity and specificity with bootstrap estimation (100 boot-
strap replications). Contingency tables then identify clinically
relevant cut points within the identified locations. Cohen’s
kappa is used to quantify agreement with PASI-based defini-
tions. This statistic is inflated due to the definitions of
response being based on the same PASI value, so should be
treated with caution. Cohen’s kappa 041–060, 061–080
and > 080 indicate moderate, substantial and almost perfect
agreements, respectively.
Sensitivity analyses were used to investigate the impact of
treatment (biologic vs. nonbiologic systemic agents), timing
of assessment (6 months vs. 12 months following start of
treatment; 2013–2015 vs. 2016–2018; baseline PASI assess-
ment on treatment start date vs. prior to treatment start date)
and baseline disease severity (PASI < 10, 10–20, > 20). The
time periods 2013–2015 and 2016–2018 were selected to
assess for any effect of the recent introduction of more effica-
cious biologic agents.
Exploring the relationship between Psoriasis Area and
Severity Index and Physician’s Global Assessment (PGA),
and establishing PGA response and eligibility definitions
The relationship between PASI and PGA was assessed graphi-
cally using box and whisker plots and quantified using Spear-
man’s rank correlation coefficient. The approach described
above was used to evaluate the potential impact of changing
from PASI to PGA in clinical practice. We thus used the abso-
lute PASI threshold corresponding to the most commonly used
relative PASI definition of treatment response (PASI 90)13 and
PASI-based NICE criteria for biologics eligibility (PASI ≥ 10)9
to derive PGA-based definitions for response and biologic eli-
gibility. Cohen’s kappa was used to quantify agreement
between PASI- and PGA-based definitions. All patients
included in the analysis had both a PGA and PASI recorded on
the same day postbaseline. All analyses are on a complete-case
basis and were conducted in Stata 15 (StataCorp, College Sta-
tion, TX, U.S.A.).17
Results
Cohort characteristics
Data from 13 422 patients with psoriasis enrolled in BADBIR
are included. Of these, 9201 patients received a biologic agent
(‘biologic cohort’) and 4221 patients received a nonbiologic
systemic treatment (‘nonbiologic systemic cohort’) (Table 1;
and Table S1; see Supporting Information). In total 1371
patients switched from the nonbiologic systemic cohort to the
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biologic cohort and are therefore included in the analysis twice.
Hence, data from 12 051 patients are unique. Patients had con-
secutive outcome assessments performed over a median of 338
days (interquartile range 252–386, range 0–7530).
The baseline characteristics of the participants are listed in
Table 1 and are in line with those from previous reports.15,18
The average baseline PASI was 154  81 and 583% are
male. The average age and body mass index of participants are
449  135 years and 308  72 kg m2, respectively.
Almost all participants have chronic plaque psoriasis (988%)
and 189% have concurrent psoriatic arthritis.
Psoriasis Area and Severity Index (PASI) ≤ 2 is
consistent with PASI 90 response
Response status (i.e. responder or nonresponder) was assigned
according to PASI 90 status. The relative PASI response was
derived from 23 501 longitudinal PASI measurements in
10 894 patients, in which each patient has a baseline PASI
and at least one follow-up PASI recorded. When balancing
sensitivity and specificity, the ROC curve analysis indicates that
an absolute PASI threshold around 16 [95% confidence inter-
val (CI) 15–17] is consistent with PASI 90 response. To
Table 1 Baseline characteristics of the BADBIR cohort
Biologic cohort
(n = 9201)
Nonbiologic systemic
cohort (n = 4221) Overall (n = 13 422)a
Disease duration (years), mean  SD 217  126 187  133 207  129
n = 9134 n = 4202 n = 13 336
Age of onset (years), mean  SD 233  135 255  153 240  141
n = 9185 n = 4216 n = 13 401
Baseline PASI score, mean  SD 157  81 148  80 154  81
n = 7948 n = 3957 n = 11 905
Baseline DLQI score, mean  SD 174  77 156  71 167  75
n = 4683 n = 3054 n = 7737
Baseline PGA score n = 6584 n = 3593 n = 10 177
Severe 2111 (321) 870 (242) 2981 (293)
Moderate–severe 2869 (436) 1510 (420) 4379 (430)
Moderate 1312 (199) 924 (257) 2236 (220)
Mild 180 (27) 198 (55) 378 (37)
Almost clear 81 (12) 71 (20) 152 (15)
Clear 31 (05) 20 (06) 51 (05)
Sex male 5455 (593) 2366 (561) 7821 (583)
n = 9201 n = 4221 n = 13 422
White ethnicity 8391 (914) 3800 (904) 12 191 (911)
n = 9179 n = 4202 n = 13 381
Age (years), mean  SD 451  131 443  144 449  135
n = 9201 n = 4221 n = 13 422
Body mass index (kg m2) n = 8585 n = 3912 n = 12 497
Mean  SD 311  72 302  71 308  72
Underweight (< 185) 71 (08) 56 (14) 127 (10)
Normal weight (185–249) 1530 (178) 864 (221) 2394 (192)
Overweight (250–299) 2718 (317) 1296 (331) 4014 (321)
Obese class I (300–349) 2154 (251) 900 (230) 3054 (244)
Obese class II (350–399) 1199 (140) 423 (108) 1622 (130)
Obese class III (≥ 400) 913 (106) 373 (95) 1286 (103)
Smoking status n = 8019 n = 3711 n = 11 730
Never smoked 2724 (340) 1124 (303) 3848 (328)
Previously smoked 2902 (362) 1328 (358) 4230 (361)
Currently smokes 2393 (298) 1259 (339) 3652 (311)
Chronic plaque psoriasis 9098 (989) 4169 (988) 13 267 (988)
n = 9201 n = 4221 n = 13 422
Psoriatic arthritis at baseline 2096 (228) 441 (104) 2537 (189)
n = 9201 n = 4221 n = 13 422
Other type(s) of psoriasisb 2210 (241) 1105 (262) 3315 (248)
n = 9169 n = 4214 n = 13 383
The data are presented as n (%) unless stated otherwise. PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index;
PGA, Physician’s Global Assessment. a1371 patients switched from a nonbiologic systemic to a biologic agent so are included in these
summaries twice. There are therefore 12 051 unique patients overall. bErythrodermic, guttate, generalized pustular, localized pustular or
unstable.
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optimize potential practical utility, we explored absolute PASI
thresholds of 2 and 15 (Table 2).
PASI ≤ 2 assigns the same response status as PASI 90 in
90% of cases, with a Cohen’s kappa of 078 (95% CI 077–
079), indicating substantial agreement (Table 2, Fig. 1a).
PASI ≤ 15 assigns the same response status as PASI 90 in
93% of cases (Cohen’s kappa 085, 95% CI 084–086);
however, 3% of cases are classified as nonresponders using
PASI ≤ 15 but are responders according to PASI 90 status.
This reduces to 1% using PASI ≤ 2, indicating a more fre-
quent correct assignment of PASI 90 response status (i.e.
fewer false negative classifications) with this higher absolute
threshold. These PASI 90 responders who are classified as
nonresponders according to an absolute PASI threshold of 2
necessarily have more severe disease (mean  SD baseline
PASI 33.5  8.9 vs. mean baseline PASI 15.4  81 for the
whole cohort).
Overall, 4% of cases are classified as responders using PASI
≤ 15 but are nonresponders according to PASI 90. This
increases to 9% for PASI ≤ 2 as this higher threshold is more
liberal for assigning responder status. Cases classified in this
way using PASI ≤ 2 necessarily have milder disease pretreat-
ment (mean baseline PASI 10.2  42 vs. mean baseline PASI
15.4  81 for the whole cohort). This highlights the inher-
ent mathematical constraints of achieving a relative PASI 90
response with a low baseline PASI.
Psoriasis Area and Severity Index ≤ 4 is consistent with
PASI 75 response
The ROC curve analysis indicates that an absolute PASI thresh-
old around 33 (95% CI 30–35) is concordant with PASI 75
response. We therefore explored the more practical absolute
definitions of PASI ≤ 3, PASI ≤ 35 and PASI ≤ 4 (Table 2). By
applying the same logic as described above for PASI 90, an
absolute PASI ≤ 4 was identified as concordant with PASI 75.
The agreement between PASI 75 and PASI ≤ 4 is 88%, with a
Cohen’s kappa 076 (95% CI 075–077) (Fig. 1b).
Psoriasis Area and Severity Index correlates with
Physician’s Global Assessment
PASI and PGA were both recorded on the same day on
23 475 occasions in 11 501 patients. There is a strong posi-
tive Spearman’s rank correlation coefficient of 092 between
PASI and PGA (Fig. 2), as the median PASI decreases progres-
sively from 192 (interquartile range 146–250) for PGA sev-
ere to 0 (interquartile range 0–0) for PGA clear (Table S2; see
Supporting Information). However, there is large variability in
the PASI score within each PGA category, as the range of PASI
values overlaps across PGA categories (Fig. 2).
Physician’s Global Assessment clear or almost clear can
be used interchangeably with Psoriasis Area and
Severity Index ≤ 2
PASI ≤ 2 is consistent with PGA clear or almost clear in 90%
of cases, with a Cohen’s kappa of 079 (95% CI 078–080),
indicating substantial agreement (Table 3, Fig. 3a). PASI ≤ 4
is concordant with PGA mild or better (i.e. PGA mild, almost
clear or clear) in 90% of cases, with a Cohen’s kappa of 077
(95% CI 077–078), indicating substantial agreement
(Table 3).
Table 2 Comparison of absolute Psoriasis Area and Severity Index
(PASI) definitions of response with PASI 90 and PASI 75. These data
are derived from 23 501 PASI measurements in 10 894 patients
PASI 90
No Yes
PASI ≤ 15 No 14 817 (63) 606 (3)
Yes 979 (4) 7099 (30)
PASI ≤ 16 No 14 622 (62) 506 (2)
Yes 1174 (5) 7199 (31)
PASI ≤ 2a No 13 619 (58) 236 (1)
Yes 2177 (9) 7469 (32)
PASI 75
No Yes
PASI ≤ 3 No 9814 (42) 1386 (6)
Yes 1105 (5) 11 196 (48)
PASI ≤ 33 No 9532 (41) 1092 (5)
Yes 1387 (6) 11 490 (49)
PASI ≤ 35 No 9359 (40) 951 (4)
Yes 1560 (7) 11 631 (49)
PASI ≤ 4b No 8737 (37) 582 (2)
Yes 2182 (9) 12 000 (51)
The data are presented as n (%). aFor PASI 90 and PASI ≤ 2:
agreement 90%, Cohen’s kappa 078 (95% confidence interval
077–079). bFor PASI 75 and PASI ≤ 4: agreement 88%,
Cohen’s kappa 076 (95% confidence interval 075–077).
10%
90%
(a)
12%
88%
(b)
Agreement Disagreement
Fig 1. Agreement between (a) ≥ 90% improvement in Psoriasis Area
and Severity Index (PASI 90) and absolute PASI ≤ 2, and (b) PASI 75
and PASI ≤ 4. The blue segment represents the agreement between the
two definitions and the grey segment represents the disagreement.
These data are derived from 23 501 longitudinal PASI measurements
in 10 894 patients.
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Physician’s Global Assessment moderate–severe or
severe is equivalent to the National Institute for Health
and Care Excellence biologics eligibility criterion of
Psoriasis Area and Severity Index ≥ 10
PASI and PGA were both recorded at baseline in 10 154
patients. In 81% of cases PGA moderate–severe or severe was
consistent with the PASI-based NICE eligibility criteria for bio-
logic therapy (PASI ≥ 10) (Table 4, Fig. 3b). The Cohen’s
kappa of 046 (95% CI 044–048) indicates moderate agree-
ment. In 3% of cases, eligibility would be gained under this
PGA-based definition, despite not satisfying current PASI-based
criteria. Conversely, 15% of people with PASI ≥ 10 would
become ineligible for biologics according to this PGA
definition.
Sensitivity analysis
Sensitivity analyses show that all of the results are robust to
the type of treatment, timing of assessments and baseline PASI
(Table S3; see Supporting Information).
Discussion
This study is the first real-world systematic evaluation of abso-
lute measures of disease control in psoriasis to date and is thus
relevant for routine clinical practice, trials investigators and
regulatory agencies. Using a multicentre cohort of more than
13 000 patients, we demonstrate that an absolute PASI ≤ 2
corresponds with PASI 90 response and is a relevant disease
end point for treat-to-target approaches in psoriasis, obviating
the need for baseline disease severity measurements. We also
show that PASI and PGA are strongly correlated, and propose
PGA moderate–severe/severe as an alternative eligibility crite-
rion to PASI-based definitions for biologics, and PGA clear/al-
most clear as an appropriate treatment end point.
Our study serves as the first validation of growing expert
opinion supporting the use of absolute rather than relative
measures of disease severity as treatment end points in psoria-
sis.10,19 A recent consensus opinion paper based on the Delphi
methodology proposed that absolute PASI ≤ 2 should be the
pursued PASI goal, as it was felt to correlate better than rela-
tive PASI with the health-related quality-of-life measure
DLQI.20 Our data support current trends in trial practices,
whereby the proportions of patients achieving absolute PASI
Spearman's rank correlation coefficient = 0.92
0
20
40
60
P
A
S
I
Clear Almost clear Mild Moderate Moderate-severe Severe
PGA
Fig 2. Correlation between Physician’s Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI). These data are derived from 23 475
occasions in 11 501 patients in which PASI and PGA were both recorded on the same day.
Table 3 Comparison of Physician’s Global Assessment (PGA)
definitions of response with proposed absolute Psoriasis Area and
Severity Index (PASI) definitions of response. These data are derived
from 23 475 occasions in which PASI and PGA were both recorded
on the same day, in 11 501 patients
PASI ≤ 2
No Yes
PGA clear or almost cleara No 12 084 (51) 824 (4)
Yes 1572 (7) 8995 (38)
PASI ≤ 4
No Yes
PGA clear, almost
clear or mildb
No 7175 (31) 407 (2)
Yes 2055 (9) 13 838 (59)
The data are presented as n (%). aAgreement 90%, Cohen’s
kappa 079 (95% confidence interval 078–080). bAgreement
90%, Cohen’s kappa 077 (95% confidence interval 077–078).
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020) 182, pp1158–1166
Psoriasis treat to target: defining outcomes in psoriasis, S.K. Mahil et al. 1163
values are increasingly reported as secondary end points due
to the recognition that these values may be more clinically
meaningful than relative PASI measures.21,22
In daily practice, where baseline PASI is often lower than in
clinical trials due to switching between systemic agents,
achieving a PASI 90 response has been shown to represent an
unrealistic treatment goal. A recent multicentre prospective
study using the BioCAPTURE Dutch cohort showed that an
absolute PASI ≤ 2 was more often achieved than PASI 90 at
week 24 of biologic therapy (242% vs. 148%, respec-
tively).23 This real-world relative PASI response rate is sub-
stantially lower than those reported in randomized controlled
trials of the same biologics (adalimumab, etanercept, inflix-
imab, ustekinumab), in which PASI 90 was achieved in 20–
58% of patients at weeks 16–28.24–27 This underscores the
relevance of absolute disease scores for defining clinically
viable treat-to-target strategies (as derived in our study), and
holds great promise for improving real-world patient out-
comes.
As the limitations of the PASI are well recognized,28,29 the
European Medicines Agency and U.S. Food and Drug Admin-
istration recommend that it is used in conjunction with PGA
to assess efficacy and inform licensing of new treatments.13,30
Clinicians are facing increasing time and resource pressures in
the context of a rising global prevalence of psoriasis,1,31 so
PGA is often used in preference to PASI measurements in
real-world settings. We validate this approach by demonstrat-
ing a close correlation between PGA and PASI, irrespectively
of treatment modality. This substantiates findings from a
meta-analysis of 30 randomized controlled trials of biologic
agents in moderate–severe psoriasis (using varying PGA Likert
scales), which demonstrated a correlation coefficient of 092
(P < 001) between PASI 75 responses and PGA clear or
almost clear for study weeks 8–16.29 Assessment of PASI 90
responses was not within the scope of the meta-analysis;
however, PASI 90 has been subsequently shown to correlate
significantly with an Investigator’s Global Assessment (six-
point Likert scale) of clear or almost clear in a phase IIb trial
of secukinumab 150 mg monthly dosing (481% clear or
almost clear and 519% PASI 90 at week 12).32 Given that
PGA clear or almost clear correctly classifies nearly all PASI 90
responses in our real-world dataset, the use of PGA clear or
nearly clear may be a justified descriptor of PASI 90 in rou-
tine practice.
Our proposed eligibility criterion for biologic therapy of
PGA moderate–severe or severe is in keeping with U.S. guide-
lines12 and could be rapidly adopted into daily clinical prac-
tice due to the ease of measurement of categorical as
opposed to quantitative variables. We have used the U.K.
healthcare model to explore the potential impact of switching
to the PGA. Despite not accounting for the extent of body
surface involvement, our PGA-based eligibility criterion
would not result in a substantial increase in the number of
eligible patients compared with the PASI-based criterion used
in current U.K. guidelines,9 and therefore would not be
expected to have a major impact on current cost-effectiveness
modelling for biologic therapies. However, as 15% of eligible
cases become ineligible for a biologic using this PGA crite-
rion, we propose that at least one of PGA moderate–severe/
severe and PASI ≥ 10 is considered the eligibility criterion in
routine practice. Importantly, according to our proposed PGA
criterion, individuals may be considered for biologic therapy
if they have a lower PASI but severe, localized disease on sites
that are associated with high functional impairment or dis-
tress (e.g. the face or genitals).33
The major strengths of this study are the large sample size,
high external validity conferred by the participation of multi-
ple centres across the U.K. and Republic of Ireland14 and fully
independent data analysis. Detailed data capture occurred at
any point in the treatment cycle, spanned a wide time frame
(2005–2018) and allowed for analysis of both nonbiologic
systemic and biologic therapies, which maximizes the general-
izability of our findings.
The limitations of the study include the predominant inclu-
sion of patients with moderate–severe disease, as the dataset
10%
90%
(a)
19%
81%
(b)
Agreement Disagreement
Fig 3. Agreement between (a) Physician’s Global Assessment (PGA)
clear or almost clear and Psoriasis Area and Severity Index (PASI) ≤ 2,
and (b) PGA moderate–severe or severe and PASI ≥ 10. The blue
segment represents the agreement between the two definitions and the
grey segment represents the disagreement. The data in (a) are derived
from 23 475 occasions in 11 501 patients in which PASI and PGA
were both recorded on the same day. The data in (b) are derived
from 10 154 patients for whom PASI and PGA were both recorded at
baseline.
Table 4 Comparison of the Psoriasis Area and Severity Index (PASI)-
based National Institute for Health and Care Excellence (NICE)
biologics eligibility criterion (PASI ≥ 10) with the Physician’s Global
Assessment (PGA)-based eligibility criterion. These data are derived
from 10 154 patients in whom PASI and PGA were both recorded at
baseline
PASI ≥ 10, n (%)
No Yes
PGA moderate–severe or severe No 1255 (12) 1557 (15)
Yes 338 (3) 7004 (69)
Agreement 81%, Cohen’s kappa 046 (95% confidence interval
044–048).
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relates to individuals qualifying for or already receiving a sys-
temic agent. Correlation with patient-reported measures such
as DLQI was out of the scope of this study. Data were col-
lected for other purposes, such as to justify commencing a
biologic agent, which may introduce potential distortions in
the dataset such as inflated baseline severity scores. The gener-
alizability of our PGA data is limited by the lack of universal
adoption of a single PGA score in routine practice and clinical
trials, or by regulatory agencies.34 However, most do employ
the six-point score to rate disease severity from ‘clear’ to ‘sev-
ere’ that was used for our study.13,30
As it is likely that PGA and PASI are simultaneously mea-
sured by the same assessor, the concordance between these
scores may be inflated, as the first measurement may bias the
second. The order in which the PASI and PGA are measured
may also therefore be relevant. However, the potential influ-
ence of these factors on our results is limited by the consecu-
tive measurement of scores throughout the treatment cycle for
each individual.
Finally, our dataset is based on the currently available sys-
temic and biologic therapies for psoriasis; however, the thera-
peutic armamentarium for psoriasis is undergoing a rapid
expansion, with several agents recently approved for use or
awaiting imminent approval.3 As these newer agents offer
comparable or better efficacy rates compared with the analysed
treatments, our proposed stringent end points are likely to
remain relevant. We also demonstrated the robustness of our
findings in different time windows, thereby indicating negligi-
ble influence of drug class.
In conclusion, as skin clearance or near clearance is now a
realistic outcome for treatment of psoriasis, irrespectively of
baseline disease severity, this study proposes up-to-date treat-
ment goals based on real-world data. We demonstrate that an
absolute PASI ≤ 2 is a relevant and practical disease end point
in psoriasis, which could be used to define treat-to-target
approaches in routine clinical settings. If adopted, this para-
digm shift in psoriasis care would align its clinical practice
with that of other chronic diseases such as diabetes and hyper-
tension, wherein patients are treated to the goal of ‘normaliza-
tion’ in order to prevent end organ damage (e.g. cardiac
events).35 Our data also highlight PGA severity scores as alter-
natives to PASI for treatment eligibility criteria and measures of
response, which is likely to be highly clinically viable. Future
analysis of patient and clinician acceptability of our proposed
criteria will yield additional important data on clinical utility.
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